Recent advances of dual FGFR inhibitors as a novel therapy for cancer

Tumour-associated macrophages as treatment targets in oncology

Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,065 · see citing works

Tumour-educated macrophages promote tumour progression and metastasis

Pollard, J. W. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1256 · Cited by 3,365 · see citing works

Modes of resistance to anti-angiogenic therapy

Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · see citing works

Fibroblast growth factor signalling: from development to cancer

Turner, N., & Grose, R. (2010) · Nature Reviews. Cancer · doi:10.1038/nrc2780 · Cited by 2,689 · see citing works

PI3K pathway alterations in cancer: variations on a theme

Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845 · see citing works

The emerging mechanisms of isoform-specific PI3K signalling

Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2882 · Cited by 1,767 · see citing works

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564 · see citing works

Macrophages, innate immunity and cancer: balance, tolerance, and diversity

Mantovani, A., & Sica, A. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.009 · Cited by 1,484 · see citing works

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.

Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L. P., Feuerhake, F., Klaman, I., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.016 · Cited by 1,384 · see citing works

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

Faivre, S. J., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C. L., DePrimo, S. E., Brega, N. M., Massimini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2194 · Cited by 1,162 · see citing works

Advances and challenges in targeting FGFR signalling in cancer

Babina, I. S., & Turner, N. C. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.8 · Cited by 815 · see citing works

Brivanib versus sorafenib as first‐line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK‐FL study

Johnson, P. J., Qin, S., Park, J.-W., Poon, R. T. P., Raoul, J.-L., Philip, P. A., Hsu, C.-H., Hu, T.-H., Heo, J., Xu, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4410 · Cited by 772 · see citing works

The regulation and function of Class III PI3Ks: novel roles for Vps34

Backer, J. (2008) · Biochemical Journal · doi:10.1042/bj20071427 · Cited by 659 · see citing works

Colony-stimulating factor-1 in immunity and inflammation

Chitu, V., & Stanley, E. R. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.11.006 · Cited by 635 · see citing works

Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor

Zhao, Y., & Adjei, A. A. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0465 · Cited by 560 · see citing works

Targeting FGFR Signaling in Cancer

Touat, M., Ileana, E. E., Postel-Vinay, S. C., André, F., & Soria, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2329 · Cited by 531 · see citing works

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

Shimizu, T., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Smith, L. S., Gunn, S., Smetzer, L., Mays, T. A., Kaiser, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2381 · Cited by 431 · see citing works

FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)

Katoh, M. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2620 · Cited by 405 · see citing works

Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer

Tan, C., Gilligan, D., & Pacey, S. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00246-6 · Cited by 390 · see citing works

Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant

Huang, W., Metcalf, C. A., Sundaramoorthi, R., Wang, Y., Zou, D., Thomas, R. M., Zhu, X., Cai, L., Wen, D., Liu, S., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100395q · Cited by 378 · see citing works

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

Dienstmann, R., Rodon, J. A., Prat, A., Pérez-García, J. M., Adamo, B., Felip, E., Cortés, J., Iafrate, A. J., Nuciforo, P. G., & Tabernero, J. M. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt419 · Cited by 370 · see citing works

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

Trudel, S., Li, Z.-H., Wei, E., Wiesmann, M., Chang, H., Chen, C., Reece, D., Heise, C., & Stewart, A. (2004) · Blood · doi:10.1182/blood-2004-10-3913 · Cited by 302 · see citing works

Oncogenic Mutations of PIK3CA in Human Cancers

Samuels, Y., & Waldman, T. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_68 · Cited by 291 · see citing works

Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia

Ceccacci, E., & Minucci, S. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.36 · Cited by 256 · see citing works

Discoidin Domain Receptors: Unique Receptor Tyrosine Kinases in Collagen-mediated Signaling

Fu, H.-L., Valiathan, R. R., Arkwright, R. T., Sohail, A., Mihai, C., Kumarasiri, M., Mahasenan, K. V., Mobashery, S., Huang, P. H., Agarwal, G., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.444158 · Cited by 248 · see citing works

Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling

Qian, C., Lai, C.-J., Bao, R., Wang, D.-G., Wang, J., Xu, G.-X., Atoyan, R., Qu, H., Yin, L., Samson, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0055 · Cited by 248 · see citing works

Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms

Hughes, D., & Andersson, D. I. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3922 · Cited by 243 · see citing works

CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity

Lai, C.-J., Bao, R., Tao, X., Wang, J., Atoyan, R., Qu, H., Wang, D.-G., Yin, L., Samson, M., Forrester, J. S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3360 · Cited by 214 · see citing works

FGFR a promising druggable target in cancer: Molecular biology and new drugs

Porta, R., Borea, R., Coelho, A., Khan, S., Araújo, A., Reclusa, P., Franchina, T., Steen, N. V. D., van Dam, P. A., Ferri, J., et al. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.018 · Cited by 201 · see citing works

Histone deacetylases: structural determinants of inhibitor selectivity

Micelli, C., & Rastelli, G. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.01.007 · Cited by 196 · see citing works

Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region–Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib

Ren, X., Pan, X., Zhang, Z., Wang, D., Lu, X., Li, Y., Wen, D., Long, H., Luo, J., Feng, Y., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301581y · Cited by 195 · see citing works

Distinct Role of Fibroblast Growth Factor-2 and Vascular Endothelial Growth Factor on Tumor Growth and Angiogenesis

Giavazzi, R., Sennino, B., Coltrini, D., Garofalo, A., Dossi, R., Ronca, R., Molinari-Tosatti, M. P., & Presta, M. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64325-8 · Cited by 185 · see citing works

In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models

Lee, S.-H., de Menezes, D. E. L., Vora, J., Harris, A., Ye, H., Nordahl, L., Garrett, E., Samara, E., Aukerman, S., Gelb, A., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2129 · Cited by 184 · see citing works

Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors

Tan, L., Wang, J., Tanizaki, J., Huang, Z., Aref, A. R., Rusan, M., Zhu, S.-J., Zhang, Y., Ercan, D., Liao, R. G., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403438111 · Cited by 178 · see citing works

Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status

An, S., Chen, Z. H., Su, J., Zhang, X., Zhong, W.-Z., Yang, J., Zhou, Q. H., Yang, X.-N., Huang, L., Guan, J.-L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040109 · Cited by 177 · see citing works

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors

Soria, J., de Braud, F., Bahleda, R., Adamo, B., André, F., Dienstmann, R., Delmonte, A., Cereda, R., Isaacson, J., Litten, J. B., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu390 · Cited by 175 · see citing works

Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders

van Rhijn, B. V., van Tilborg, A. V., Lurkin, I., Bonaventure, J., de Vries, A., Thiery, J., van der Kwast, T., Zwarthoff, E., & Radvanyi, F. (2002) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5200883 · Cited by 155 · see citing works

E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models

Bello, E., Colella, G., Scarlato, V., Oliva, P., Berndt, A., Valbusa, G., Serra, S. C., D’Incalci, M., Cavalletti, E., Giavazzi, R., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2700 · Cited by 143 · see citing works

Discovery of Brivanib Alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215)

Cai, Z., Zhang, Y., Borzilleri, R. M., Qian, L., Barbosa, S. A. L., Wei, D. D., Zheng, X., Wu, L., Fan, J., Shi, Z., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7013309 · Cited by 142 · see citing works

Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures

Lee, K. H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.001 · Cited by 142 · see citing works

Discovery and Preclinical Studies of (R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an In Vivo Active Potent VEGFR-2 Inhibitor

Bhide, R. S., Cai, Z., Zhang, Y., Qian, L., Wei, D. D., Barbosa, S. A. L., Lombardo, L. J., Borzilleri, R. M., Zheng, X., Wu, L. I., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051106d · Cited by 133 · see citing works

Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type K-RAS Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial

Siu, L. L., Shapiro, J. D., Jonker, D. J., Karapetis, C. S., Zalcberg, J. R., Simes, J. R., Couture, F., Moore, M. J., Price, T. J., Siddiqui, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.0543 · Cited by 126 · see citing works

Targeting the fibroblast growth factor receptor family in cancer

Hallinan, N., Finn, S. P., Cuffe, S. D., Rafee, S., O'Byrne, K. J., & Gately, K. A. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.015 · Cited by 125 · see citing works

Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy

Musolino, A., Campone, M., Neven, P., Denduluri, N., Barrios, C. H., Cortés, J., Blackwell, K., Soliman, H. H., Kahán, Z., Bonnefoi, H. R., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0807-8 · Cited by 114 · see citing works

Platelet-Derived Growth Factor Signaling in the Lung. From Lung Development and Disease to Clinical Studies

Noskovičová, N., Petřek, M., Eickelberg, O., & Heinzelmann, K. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0294tr · Cited by 111 · see citing works

Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors

Brameld, K. A., Owens, T. D., Verner, E. J., Venetsanakos, E., Bradshaw, J. M., Phan, V. T., Tam, D., Leung, K., Shu, J., LaStant, J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00360 · Cited by 104 · see citing works

Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer

Tong, C. W. S., Wu, W. K. K., Loong, H. H.-F., Cho, W. C. S., & To, K. K. W. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.07.023 · Cited by 100 · see citing works

Discoidin domain receptor 2 is a critical regulator of epithelial–mesenchymal transition

Walsh, L. A., Nawshad, A., & Medici, D. (2011) · Matrix Biology · doi:10.1016/j.matbio.2011.03.007 · Cited by 94 · see citing works

A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study

Powell, M. A., Sill, M. W., Goodfellow, P. J., Benbrook, D. M., Lankes, H. A., Leslie, K. K., Jeske, Y. W. A., Mannel, R. S., Spillman, M. A., Lee, P. S., et al. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.07.083 · Cited by 91 · see citing works

Dual-target kinase drug design: Current strategies and future directions in cancer therapy

Sun, D., Zhao, Y., Zhang, S., Zhang, L., Liu, B., & Ouyang, L. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.112025 · Cited by 88 · see citing works

Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein

Wang, Y., Ding, X., Wang, S., Moser, C. D., Shaleh, H. M., Mohamed, E. A., Chaiteerakij, R., Allotey, L. K., Chen, G., Miyabe, K., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.05.017 · Cited by 87 · see citing works

Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides

Eldehna, W. M., Kerdawy, A. M. E., Al-Ansary, G. H., Al‐Rashood, S. T., Ali, M. M., & Mahmoud, A. E. E.-D. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.061 · Cited by 85 · see citing works

Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma

Keam, B., Kim, S., Shin, S. H., Cho, B. C., Lee, K., Kim, M. K., Yun, H., Lee, S., Yoon, D. H., & Bang, Y. (2015) · Cancer · doi:10.1002/cncr.29401 · Cited by 82 · see citing works

Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion

Wang, J., Pursell, N. W., Samson, M., Atoyan, R., Ma, A. W., Selmi, A., Xu, W., Cai, X., Voi, M., Savagner, P., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1045 · Cited by 82 · see citing works

Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects

Li, D., Xie, K., Zhang, L., Yao, X., Li, H., Xu, Q., Wang, X., Jiang, J., & Fang, J. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.04.036 · Cited by 82 · see citing works

Molecular therapeutic targets in non-small cell lung cancer

Sankar, K. N., Gadgeel, S. M., & Qin, A. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1787156 · Cited by 81 · see citing works

FGFR3 mutations in prostate cancer: association with low-grade tumors

Hernandez, S. F., de Muga, S., Agell, L., Juanpere-Rodero, N., Esgueva, R., Lorente, J. A., Mojal, S., Serrano, S., & Lloreta, J. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.46 · Cited by 75 · see citing works

Immuno-oncologists eye up macrophage targets

Morrison, C. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.111 · Cited by 75 · see citing works

FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells

Yuan, H., Li, Z., Shao, J., Ji, W., Xia, W., & Lu, S. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0534-0 · Cited by 74 · see citing works

Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation

Rosty, C., Aubriot, M., Cappellen, D., Bourdin, J., Cartier, I., Thiery, J., Sastre-Garau, X., & Radvanyi, F. (2005) · Molecular Cancer · doi:10.1186/1476-4598-4-15 · Cited by 70 · see citing works

FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy

Quintanal-Villalonga, À., Molina‐Pinelo, S., Cirauqui, C., Ojeda-Márquez, L., Marrugal, Á., Suárez, R. A., Conde, E., Ponce-Aix, S., Enguita, A. B., Carnero, A., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.12.021 · Cited by 70 · see citing works

Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer

Yu, S., Cai, X., Wu, C., Liu, Y., Zhang, J., Gong, X., Wang, X., Wu, X., Zhu, T., Mo, L., et al. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.18834 · Cited by 66 · see citing works

Dovitinib (CHIR258, TKI258): Structure, Development and Preclinical and Clinical Activity

Porta, C., Giglione, P., Liguigli, W., & Paglino, C. (2015) · Future Oncology · doi:10.2217/fon.14.208 · Cited by 64 · see citing works

The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib

Parker, W. T., Yeung, D. T. O., Yeoman, A. L., Altamura, H. K., Jamison, B. A., Field, C. R., Hodgson, J., Lustgarten, S., Rivera, V. M., Hughes, T. P., et al. (2016) · Blood · doi:10.1182/blood-2015-09-666214 · Cited by 64 · see citing works

Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives

Tomasello, C., Baldessari, C., Napolitano, M., Orsi, G., Grizzi, G., Bertolini, F., Barbieri, F., & Cascinu, S. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.01.013 · Cited by 64 · see citing works

Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling

Nakamura, I., Zakharia, K., Banini, B. A., Mikhail, D. S., Kim, T. H., Yang, J. D., Moser, C. D., Shaleh, H. M., Thornburgh, S. R., Walters, I. B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092273 · Cited by 63 · see citing works

Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy

Kim, S.-M., Kim, H.-D., Yun, M. R., Kang, H., Pyo, K.-H., Park, H. J., Lee, J. M., Choi, H., Ellinghaus, P., Ocker, M., et al. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.48 · Cited by 63 · see citing works

Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors

Wong, J. P.-M., Todd, J. R., Finetti, M. A., McCarthy, F., Broncel, M., Vyse, S., Luczynski, M. T., Crosier, S., Ryall, K. A., Holmes, K., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.005 · Cited by 62 · see citing works

Personalized therapy on the horizon for squamous cell carcinoma of the lung

Kim, H. S., Mitsudomi, T., Soo, R. A., & Cho, B. C. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.02.015 · Cited by 61 · see citing works

Design, synthesis and evaluate of novel dual FGFR1 and HDAC inhibitors bearing an indazole scaffold

Liu, J., Qian, C., Zhu, Y., Cai, J., He, Y., Li, J., Wang, T., Zhu, H., Li, Z., Li, W., et al. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.12.041 · Cited by 61 · see citing works

The role of HGF/MET and FGF/FGFR in fibroblast-derived growth stimulation and lapatinib-resistance of esophageal squamous cell carcinoma

Saito, S., Morishima, K., Ui, T., Hoshino, H., Matsubara, D., Ishikawa, S., Aburatani, H., Fukayama, M., Hosoya, Y., Sata, N., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1065-8 · Cited by 60 · see citing works

Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer

Chen, C., Changou, C. A., Hsieh, T., Lee, Y., Chu, C.-Y., Hsu, K., Wang, H., Lin, Y., Lo, Y.-N., Liu, Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2066 · Cited by 59 · see citing works

Discoidin Domain Receptor 2 Signaling Networks and Therapy in Lung Cancer

Payne, L. S., & Huang, P. H. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000164 · Cited by 57 · see citing works

HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers

Putcha, P., Yu, J., Barrueco, R. R., Saucedo-Cuevas, L. P., Villagrasa, P., Murga-Penas, E., Quayle, S. N., Yang, M., Castro, V., Llobet‐Navàs, D., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0658-0 · Cited by 55 · see citing works

The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II

Hasinoff, B. B., Wu, X., Nitiss, J. L., Kanagasabai, R., & Yalowich, J. C. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.09.023 · Cited by 54 · see citing works

Discovery of 3-(5′-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation

Yan, W., Wang, X., Dai, Y., Zhao, B., Yang, X., Fan, J. K., Gao, Y., Meng, F., Wang, Y., Luo, C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00056 · Cited by 54 · see citing works

Design, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffold

Liu, J., Xia, P., Dai, Y., Zhang, W., Ren, S., Ai, J., Geng, M., & Li, Y. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob00778j · Cited by 45 · see citing works

Discovery of Dual FGFR4 and EGFR Inhibitors by Machine Learning and Biological Evaluation

Chen, X., Xie, W., Yang, Y., Hua, Y., Xing, G., Liang, L., Deng, C., Wang, Y., Fan, Y., Liu, H., et al. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00652 · Cited by 44 · see citing works

In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models

Guffanti, F., Chilà, R., Bello, E., Zucchetti, M., Zangarini, M., Ceriani, L., Ferrari, M., Lupi, M., Jacquet-Bescond, A., Burbridge, M. F., et al. (2016) · Neoplasia · doi:10.1016/j.neo.2016.11.008 · Cited by 40 · see citing works

Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer

Golfmann, K., Meder, L., Koker, M., Volz, C., Borchmann, S., Tharun, L., Dietlein, F., Malchers, F., Florin, A., Büttner, R., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0380-3 · Cited by 39 · see citing works

Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors

Wei, M., Xia, P., Xing, L., Dai, Y., Huang, R., Geng, M., Zhang, A., Ai, J., & Song, Z. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.05.005 · Cited by 38 · see citing works

Targeting Fibroblast Growth Factor Receptor (FGFR) and Phosphoinositide 3-kinase (PI3K) Signaling Pathways in Medulloblastoma Cell Lines

Holzhauser, S., Lukoseviciute, M., Andonova, T., Ursu, R. G., Dalianis, T., Wickström, M., & Kostopoulou, O. N. (2019) · Anticancer Research · doi:10.21873/anticanres.13925 · Cited by 36 · see citing works

ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity

Holmström, T. H., Moilanen, A., Ikonen, T., Björkman, M. L., Linnanen, T., Wohlfahrt, G., Karlsson, S., Oksala, R., Korjamo, T., Samajdar, S., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0204 · Cited by 34 · see citing works

Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models

Xia, P., Hou, P., Chen, Y., Dai, Y., Ji, Y., Shen, Y., Su, Y., Liu, B., Wang, Y., Sun, D., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1357-y · Cited by 33 · see citing works

Population Pharmacokinetic/Pharmacodynamic Modeling to Assist Dosing Schedule Selection for Dovitinib

Wang, X., Kay, A., Anak, O., Angevin, E., Escudier, B. J., Zhou, W., Feng, Y., Dugan, M. H., & SCHRAN, H. F. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011433330 · Cited by 29 · see citing works

Beneficial effects of dual vascular endothelial growth factor receptor/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats

Lin, H., Huang, Y., Yang, Y., Lee, P., Hwang, L., Lee, W., Kuo, Y., Lee, K., Hsieh, Y., & Liu, R. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12480 · Cited by 29 · see citing works

Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours

Jones, R. L., Ratain, M. J., O'Dwyer, P. J., Siu, L. L., Jassem, J., Médioni, J., deJonge, M. J. A., Rudin, C. M., Sawyer, M. B., Khayat, D., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.07.024 · Cited by 29 · see citing works

Brivanib Exhibits Potential for Pharmacokinetic Drug–Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes

Hofman, J., Sorf, A., Vagiannis, D., Sucha, S., Kammerer, S., Küpper, J., Chen, S., Guo, L., Čečková, M., & Štaud, F. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00361 · Cited by 28 · see citing works

Discovery of 4,6-pyrimidinediamine derivatives as novel dual EGFR/FGFR inhibitors aimed EGFR/FGFR1-positive NSCLC

Xie, Z., Wu, K., Wang, Y., Pan, Y., Chen, B., Cheng, D., Pan, S., Guo, T., Du, X., Fang, L., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111943 · Cited by 28 · see citing works

GZD824 as a FLT3, FGFR1 and PDGFRα Inhibitor Against Leukemia In Vitro and In Vivo

Wang, Y., Zhang, L., Tang, X., Luo, J., Tu, Z., Jiang, K., Ren, X., Xu, F., Chan, S., Li, Y., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100766 · Cited by 28 · see citing works

Cell adhesion and polarity in squamous cell carcinoma of the lung

Bonastre, E., Brambilla, E. M., & Sánchez‐Céspedes, M. (2016) · The Journal of Pathology · doi:10.1002/path.4686 · Cited by 26 · see citing works

Metabolism, Excretion, and Pharmacokinetics of Oral Brivanib in Patients with Advanced or Metastatic Solid Tumors

Mekhail, T. M., Masson, E., Fischer, B. S., Gong, J., Iyer, R. A., Gan, J., Pursley, J. M., Patricia, D., Williams, D., & Ganapathi, R. N. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.033951 · Cited by 25 · see citing works

Emerging protein kinase inhibitors for the treatment of multiple myeloma

Lind, J., Czernilofsky, F., Vallet, S., & Podar, K. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1647165 · Cited by 24 · see citing works

Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC

Gammelgaard, K. R., Vad‐Nielsen, J., Clement, M. S., Weiss, S., Daugaard, T. F., Dagnæs‐Hansen, F., Meldgaard, P., Sørensen, B. S., & Nielsen, A. L. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.11.017 · Cited by 23 · see citing works

Trichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivo

Chen, C., Liu, Y.-M., Pan, S., Liu, Y., Liou, J., & Yen, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.8380 · Cited by 22 · see citing works

Significant Antitumor Activity of E-3810, a Novel FGFR and VEGFR Inhibitor, in Patients With FGFR1 Amplified Breast Cancer

Dienstmann, R., André, F., Soria, J., Tabernero, J. M., de Braud, F., Cereda, R., Bahleda, R., Hollebecque, A., Delmonte, A., & Camboni, M. G. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(20)32898-2 · Cited by 22 · see citing works

Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents

Gangjee, A., Zhao, Y., Raghavan, S., Ihnat, M. A., & Disch, B. C. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.05.049 · Cited by 21 · see citing works

A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study

Chan, J. K., Deng, W., Higgins, R. V., Tewari, K. S., Bonebrake, A. J., Hicks, M. L., Gaillard, S. L., Ramirez, P. T., Chafe, W. E., Monk, B. J., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.05.033 · Cited by 21 · see citing works

Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer

Zhang, Y., Lv, H., Luo, L., Xu, Y., Pan, Y., Wang, Y., Lin, H., Xiong, J., Guo, P., Zhang, J., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.031 · Cited by 21 · see citing works

A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer

Campone, M., Bachelot, T., Penault-Llorca, F. M., Pallis, A. G., Agrapart, V., Pierrat, M., Poirot, C., Dubois, F., Xuereb, L., Bossard, C. J., et al. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-03765-3 · Cited by 21 · see citing works

FGFR antagonist induces protective autophagy in FGFR1-amplified breast cancer cell

Chen, Y., Xie, X., Li, X., Wang, P., Qian, J., Yue, J., Liu, Y., Cheng, Z., Li, J., Song, H., et al. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.03.017 · Cited by 20 · see citing works

SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer models

Jiang, X., Dai, Y., Xia, P., Shen, Y., Su, Y., Wei, M.-M., Liu, W., Ding, Z., Zhang, A., Shi, Y., et al. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.96 · Cited by 19 · see citing works

Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma

Wang, Q., Dai, Y., Ji, Y., Shi, H., Guo, Z., Chen, D., Chen, Y., Xia, P., Gao, Y., Wang, X., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.015 · Cited by 19 · see citing works

Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity ≤ 50%: A multi-center retrospective analysis

Senoo, S., Miyahara, N., Taniguchi, A., Oda, N., Itano, J., Higo, H., Hara, N., Watanabe, H., Kano, H., Suwaki, T., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236935 · Cited by 14 · see citing works

FGFR inhibitor AZD4547 can enhance sensitivity of esophageal squamous cell carcinoma cells with epithelial‑mesenchymal transition to gefitinib

Luo, H., Jin, Q., Xiao, H., Luo, J., Zhang, Q., Pi, G., Ye, Y., He, R. L., Liu, Y., Su, X., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6304 · Cited by 13 · see citing works

Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature

Fanelli, M., Caputo, F., Cerma, K., Gelsomino, F., Bari, A., Dominici, M., & Pozzi, S. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220950440 · Cited by 11 · see citing works

Metabolic Chiral Inversion of Brivanib and Its Relevance to Safety and Pharmacology

Gong, J., Gan, J., Masson, E., Syed, S. S., Xia, Y.-Q., Williams, D., Pursley, J. M., Jemal, M., Humphreys, W. G., & Iyer, R. A. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.047340 · Cited by 10 · see citing works

Phase I/II study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours

Bono, P., Massard, C., Peltola, K. J., Azaro, A., Italiano, A., Kristeleit, R. S., Lassen, U., Arkenau, H., Hakulinen, P., Garratt, C., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy279.408 · Cited by 4 · see citing works

The inhibition profiles of 4'‐acylpyrrole–5‐fluoroindolin‐2‐ones with a C‐3' side chain for VEGFR2, PDGFR‐β, and FGFR‐1 protein kinases

Huang, J., Lin, Y., Lai, C., Yang, S., Lin, S. F., Yang, J., Huang, H., Liu, C.-W., Wei, W., Chuang, S., et al. (2020) · Journal of the Chinese Chemical Society · doi:10.1002/jccs.201900466 · Cited by 4 · see citing works

Understanding the adverse event experience in the S-TRAC adjuvant trial of sunitinib for high-risk renal cell carcinoma

Wood, S. Y., Ryan, J. C., Clair, A. G., & George, D. J. (2020) · Future Oncology · doi:10.2217/fon-2019-0369 · Cited by 3 · see citing works

Phase 1 study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours

Rodon, J. A., Peltola, K., Azaro, A., Álvarez, E. C., Garratt, C., Leskinen, H. K., Bjorklund, H., Ruck, A., Massard, C., & Bono, P. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw368.13 · Cited by 3 · see citing works

597 Pharmacokinetics of the Novel FGFR and VEGFR Inhibitor, E-3810, in Patients with Advanced Solid Tumors Participating to a Phase I/II Trial

Zangarini, M., Sala, F., Camboni, M. G., Cereda, R., Livi, V., Bahleda, R., Dienstmann, R., Delmonte, A., D’Incalci, M., & Zucchetti, M. (2012) · European Journal of Cancer · doi:10.1016/s0959-8049(12)72394-8 · Cited by 1 · see citing works

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works

PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)

He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283 · see citing works

Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist

Li, X., Li, X., Liu, F., Li, S., & Shi, D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00683 · Cited by 191 · see citing works

FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance

Szymczyk, J., Służalska, K., Materla, I., Opalinski, L., Otlewski, J., & Zakrzewska, M. (2021) · Cancers · doi:10.3390/cancers13225796 · Cited by 80 · see citing works

Recent updates on potential of VEGFR-2 small-molecule inhibitors as anticancer agents

Chaudhari, P. J., Nemade, A. R., & Shirkhedkar, A. A. (2024) · RSC Advances · doi:10.1039/d4ra05244g · Cited by 69 · see citing works

Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy

Ye, J., Wu, J., & Liu, B. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188866 · Cited by 63 · see citing works

Discovery of novel and potent dual-targeting AXL/HDAC2 inhibitors for colorectal cancer treatment via structure-based pharmacophore modelling, virtual screening, and molecular docking, molecular dynamics simulation studies, and biological evaluation

Qiao, X., Wu, X., Chen, S., Niu, M., Hua, H., & Zhang, Y. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2295241 · Cited by 38 · see citing works

Revolutionizing Wound Healing: Exploring Scarless Solutions through Drug Delivery Innovations.

Alavi, S., Alavi, S. Z., Nisa, M., Koohi, M., Raza, A., & Shahmabadi, H. E. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c01072 · Cited by 28 · see citing works

Research progress of VEGFR small molecule inhibitors in ocular neovascular diseases

Jiang, D. Y., Xu, T., Zhong, L., Liang, Q., Hu, Y., Xiao, W., & Shi, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115535 · Cited by 30 · see citing works

Salivary glands adenoid cystic carcinoma: a molecular profile update and potential implications

da Silva, F. J., de Azevedo, J. C., Ralph, A. C. L., Pinheiro, J. D. J. V., Freitas, V. M., & Calcagno, D. Q. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1191218 · Cited by 28 · see citing works

CircARVCF Contributes to Cisplatin Resistance in Gastric Cancer by Altering miR-1205 and FGFR1

Zhang, R., Zhao, H., Yuan, H., Wu, J., Liu, H., Sun, S., Zhang, Z., & Wang, J. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.767590 · Cited by 19 · see citing works

Hyaluronic acid-FGF2-derived peptide bioconjugates for suppression of FGFR2 and AR simultaneously as an acne antagonist

Su, Z., Zhang, Y., Cao, J., Sun, Y., Cai, Y., Zhang, B., Liu, H., Zhang, Z., Xie, J., Meng, Q., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01812-7 · Cited by 18 · see citing works

Novel benzenesulfonamides as dual VEGFR2/FGFR1 inhibitors targeting breast cancer: Design, synthesis, anticancer activity and in silico studies

Hassan, R. M., Ali, I. H., Kerdawy, A. M. E., Abo-Elfadl, M. T., & Ghannam, I. A. Y. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107728 · Cited by 18 · see citing works

Structural basis and selectivity of sulfatinib binding to FGFR and CSF-1R

Lin, Q., Dai, S., Qu, L., Lin, H., Guo, M., Wei, H., Chen, Y., & Chen, X. (2024) · Communications Chemistry · doi:10.1038/s42004-023-01084-0 · Cited by 14 · see citing works

Chitosan and Its Derivative‐Based Nanoparticles in Gastrointestinal Cancers: Molecular Mechanisms of Action and Promising Anticancer Strategies

Eshkiki, Z. S., Mansouri, F., Karamzadeh, A. R., Namazi, A., Heydari, H., Akhtari, J., Tabaeian, S. P., & Akbari, A. (2024) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1155/2024/1239661 · Cited by 15 · see citing works

Metal-free oxidative decarbonylative halogenation of fused imidazoles

Singh, D., Tali, J. A., Kumar, G., & Shankar, R. (2021) · New Journal of Chemistry · doi:10.1039/d1nj04440k · Cited by 14 · see citing works

NAE modulators: A potential therapy for gastric carcinoma

Liang, Q., Liu, M., Li, J. H., Tong, R., Hu, Y., Bai, L., & Shi, J. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114156 · Cited by 11 · see citing works

A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality

Jain, N. K., Tailang, M., Thangavel, N., Makeen, H., Bratty, M. A., Najmi, A., Alhazmi, H., Zoghebi, K. A., Alagusundaram, M., Jain, H. K., et al. (2024) · Acta Pharmaceutica · doi:10.2478/acph-2024-0005 · Cited by 6 · see citing works

Current insights and barriers in FGFR-mediated signaling in lung cancer

Liu, X., Mei, W., Yao, Y., & Zeng, C. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117897 · Cited by 5 · see citing works

A Review and Update on Therapy of Gastrointestinal Tract Tumors: From the Bench to Clinical Practice

Fernández‐Aceñero, M. J., Hernández, D., & del Arco, C. D. (2024) · Journal of Clinical and Translational Pathology · doi:10.14218/jctp.2024.00007 · Cited by 4 · see citing works

Synthesis and bioassay of 3-Aryl -1-(pyridin-4-yl)benzo[4,5]imidazo[1,2-d][1,2,4]- triazin-4(3H)-ones as anti-cancer agents

Thaher, B. A. A., Almasri, I. M., Wahedy, K. M., Morjan, R. Y., Aliwaini, S. H., atter, I. M. A., Elmabhouh, A. A., ibwaini, A. K. A., Alkhaldi, S. L., Qeshta, B., et al. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02433-5 · Cited by 2 · see citing works

Strategies for Multi‐target Drug Discovery

Shi, D., & Li, X. (2024) · doi:10.1002/9781394182862.ch16 · Cited by 2 · see citing works

NF1/2 mutations predict favorable benefit from immune checkpoint inhibitor-based therapies over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma

Sun, Y., Cheng, Q., Zhou, Q., Xu, Y., Wang, G., Xu, C., Wang, W., Cai, S., & Chen, W. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01885-8 · Cited by 1 · see citing works

Novel Bicyclic Heterocycles as FGFR Inhibitors for Treating Cancer

Sabnis, R. W. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00075 · Cited by 1 · see citing works

Introduction to Cancer Genetics and Its Symbiotic Relationship

Gautam, L., Vishwakarma, M., Kanwar, I. L., Shrivastava, P., & Vyas, S. P. (2023) · Springer eBooks · doi:10.1007/978-981-19-7550-9_1

An imbalanced GLP-1R/GIPR co-agonist peptide with a site-specific N-terminal PEGylation to maximize metabolic benefits

Xia, X., Lin, Q., Zhou, Z. M., & Chen, Y. (2024) · iScience · doi:10.1016/j.isci.2024.109377

New Directions for Treating Tumors: Scientific Context

Gabriela, U. R., Costin, D., Dămian, C., Ionescu, S. G., & Smaranda, I. L. (2024) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-3-031-62520-6_74

Fibroblast Growth Factor 11 Promotes Immune Escape of Cervical Cancer Cells by Promoting Infiltration of CD4 + T Cells, Particularly Regulatory T Cells

Nie, X., Zhu, Z., Liu, Y., Zhang, X., Chen, J., Zhang, F., & Guo, B. (2025) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2024.0478

[68Ga]Ga-FAPI-46 PET imaging as a predictive indicator for therapeutic efficacy of FGFR inhibitors in preclinical model of esophageal cancer

Cui, F.-B., Sun, X., Shi, J.-M., Tang, W., Wang, H., Sun, P., Ding, D.-Q., Cao, Q., Zhang, F., Cao, X., et al. (2025) · Clinical and Translational Imaging · doi:10.1007/s40336-025-00730-y

FLT3 inhibitors in AML: from classic scaffolds to next-generation approaches

Elmenier, F. M., Dokla, E. M. E., Samir, N., Lasheen, D. S., Abouzid, K. A. M., & Ella, D. A. A. E. (2026) · RSC Advances · doi:10.1039/d6ra01319h

Indole Hybrids: Emerging EGFR‐Targeted Agents With Multifaceted Anticancer Properties (2021–Present)

Zhang, B., Wang, Y., Wen, S., Liu, Z., Zhao, B., & Lumei, D. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70334

BindingDB Entry 50022274: Research progress of VEGFR small molecule inhibitors in ocular neovascular diseases.

BindingDB (2025) · UC San Diego · doi:10.7270/q2jq15r4

BindingDB Entry 50016433: NAE modulators: A potential therapy for gastric carcinoma.

BindingDB (2023) · UC San Diego · doi:10.7270/q21c21wj

BindingDB Entry 50018278: Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist.

BindingDB (2024) · UC San Diego · doi:10.7270/q2m049nz

FGFR a promising druggable target in cancer: Molecular biology and new drugs

Porta, R., Borea, R., Coelho, A., Khan, S., Araújo, A., Reclusa, P., Franchina, T., Steen, N. V. D., van Dam, P. A., Ferri, J., et al. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.018 · Cited by 201 · see citing works

Recent Developments and Advances of FGFR as a Potential Target in Cancer

Xue, W.-J., Li, M., Chen, L., Sun, L., & Li, Y. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0103 · Cited by 39 · see citing works

FH-2001 is a novel FGFR/VEGFR dual inhibitor with immune-modulating activity

Liu, A., Huang, L., Gao, X., Liu, L., Li, X., Yu, X., & Zhao, C. (2025) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001743 · Cited by 1 · see citing works

Therapeutic implications of fibroblast growth factor receptor inhibitors in a combination regimen for solid tumors (Review)

Luo, H., Zhang, T., Cheng, P., Li, D., Ogorodniitchouk, O., Lahmamssi, C., Wang, G., & Lan, M. (2020) · Oncology Letters · doi:10.3892/ol.2020.11858 · Cited by 18 · see citing works

Future applications of FGF/FGFR inhibitors in cancer

Ghedini, G. C., Ronca, R., Presta, M., & Giacomini, A. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1491795 · Cited by 106 · see citing works